SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-22-077371
Filing Date
2022-07-05
Accepted
2022-07-05 16:30:59
Documents
2
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2220369-2_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm2220369-2_3seq1.xml 3 1552
2 EXHIBIT 24.1 tm2220369d2_ex24-1.htm EX-24.1 5176
  Complete submission text file 0001104659-22-077371.txt   8426
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Issuer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 2 SNUNIT STREET SCIENCE PARK, #455 CARMIEL L3 2161401
Business Address
Ben Zvi Shmuel (Reporting) CIK: 0001935668 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-33357 | Film No.: 221065392